Great to present phase 1b data for DLL3 ADC ZL-1310 (zoci) in platinum-refractory neuroendocrine carcinomas at #AACR26. Phase 2 is ongoin...

AACR 2026 现场信号· @ · X·2026-04-22 12:23· 2026-04-22评分60

正文 · 机器翻译

很高兴在 #AACR26 上公布 DLL3 ADC ZL-1310（zoci）治疗铂类难治性神经内分泌癌的 1b 期数据。2 期研究正在进行，我们很高兴进一步开发该药物，以治疗这些难以治疗的患者群体。@ZaiLab_Global @MSKCancerCenter @MSK_DeptOfMed https://t.co/oZzAU4ndpi

热度 26 · 21 赞 · 1 回复 · 4 转发

会议摘要

CT189NCT06885281按代号 ZL-1310 对上

Preliminary results from the phase 1b/2, open-label, multi-center study of ZL-1310, a DLL3-targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors

Rohit Thummalapalli, Ming Lu, Alexander Spira, Amr Mohamed, Rahul Aggarwal, Yu Wang, Namrata Vijayvergia, Jordi Rodon, Andrew Scott Paulson, Pingkuan Zhang, Hui Yang, Yuan Xin, Jingmin Wen, Jie Chen

读摘要原文 →

来源：AACR 2026 现场信号 · x.com